JATT Acquisition (JATT) Competitors $1.57 +0.11 (+7.53%) As of 08/5/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JATT vs. COYA, ZURA, MGNX, PLRX, CHRS, ATOS, HLVX, ANIX, ZNTL, and TCRXShould you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include Coya Therapeutics (COYA), Zura Bio (ZURA), MacroGenics (MGNX), Pliant Therapeutics (PLRX), Coherus Oncology (CHRS), Atossa Genetics (ATOS), HilleVax (HLVX), Anixa Biosciences (ANIX), Zentalis Pharmaceuticals (ZNTL), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry. JATT Acquisition vs. Its Competitors Coya Therapeutics Zura Bio MacroGenics Pliant Therapeutics Coherus Oncology Atossa Genetics HilleVax Anixa Biosciences Zentalis Pharmaceuticals TScan Therapeutics Coya Therapeutics (NASDAQ:COYA) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Do analysts prefer COYA or JATT? Coya Therapeutics currently has a consensus price target of $16.50, indicating a potential upside of 170.49%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Coya Therapeutics is more favorable than JATT Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in COYA or JATT? 39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by company insiders. Comparatively, 20.0% of JATT Acquisition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer COYA or JATT? In the previous week, Coya Therapeutics had 2 more articles in the media than JATT Acquisition. MarketBeat recorded 2 mentions for Coya Therapeutics and 0 mentions for JATT Acquisition. Coya Therapeutics' average media sentiment score of 0.84 beat JATT Acquisition's score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Coya Therapeutics Positive JATT Acquisition Neutral Which has stronger earnings & valuation, COYA or JATT? JATT Acquisition has lower revenue, but higher earnings than Coya Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$3.55M28.75-$14.88M-$1.07-5.70JATT AcquisitionN/AN/A$6.85MN/AN/A Is COYA or JATT more profitable? Coya Therapeutics' return on equity of -48.88% beat JATT Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -48.88% -43.32% JATT Acquisition N/A -49.58%2.84% SummaryCoya Therapeutics beats JATT Acquisition on 7 of the 11 factors compared between the two stocks. Get JATT Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JATT vs. The Competition Export to ExcelMetricJATT AcquisitionBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$27.08M$281.01M$5.48B$20.70BDividend YieldN/AN/A4.00%3.67%P/E RatioN/AN/A29.8828.64Price / SalesN/A461.90440.1957.35Price / Cash27.0822.4435.9423.59Price / Book-2.969.538.104.32Net Income$6.85M-$115.81M$3.26B$995.66M7 Day Performance12.14%1.09%0.65%1.91%1 Month Performance38.94%8.37%2.44%-0.54%1 Year Performance-55.52%-3.24%27.59%14.76% JATT Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JATTJATT AcquisitionN/A$1.57+7.5%N/A-58.6%$27.08MN/A0.003High Trading VolumeCOYACoya Therapeutics2.1488 of 5 stars$6.40-0.5%$16.50+157.8%+2.3%$107.54M$3.55M-5.986Upcoming EarningsZURAZura Bio3.7369 of 5 stars$1.52-3.2%$14.33+843.0%-58.1%$107.35MN/A-2.173Upcoming EarningsMGNXMacroGenics4.2626 of 5 stars$1.61-4.7%$5.33+231.3%-52.4%$106.62M$149.96M-1.81430PLRXPliant Therapeutics4.0296 of 5 stars$1.69-2.3%$13.31+687.7%-86.6%$106.20M$1.58M-0.4790News CoverageEarnings ReportCHRSCoherus Oncology3.9201 of 5 stars$0.92+0.6%$4.68+411.4%-28.7%$105.52M$266.96M-0.81330News CoverageEarnings ReportATOSAtossa Genetics2.5907 of 5 stars$0.79-2.1%$6.17+682.8%-33.6%$103.98MN/A-3.758Upcoming EarningsHLVXHilleVax1.9215 of 5 stars$2.05flat$2.00-2.4%+28.0%$102.79MN/A-0.9520News CoverageEarnings ReportUpcoming EarningsHigh Trading VolumeANIXAnixa Biosciences3.5063 of 5 stars$3.10-1.6%$9.00+190.3%-0.3%$101.46M$210K-8.165Analyst ForecastZNTLZentalis Pharmaceuticals2.4377 of 5 stars$1.38-2.1%$8.37+506.3%-55.8%$101.45M$67.43M-0.44160News CoverageEarnings ReportAnalyst ForecastTCRXTScan Therapeutics3.703 of 5 stars$1.73-1.1%$7.80+350.9%-70.8%$99.03M$2.82M-1.59100Upcoming Earnings Related Companies and Tools Related Companies COYA Alternatives ZURA Alternatives MGNX Alternatives PLRX Alternatives CHRS Alternatives ATOS Alternatives HLVX Alternatives ANIX Alternatives ZNTL Alternatives TCRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:JATT) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JATT Acquisition Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share JATT Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
